Pharmacopsychiatry 2000; 33(Suppl 1): 3-13
DOI: 10.1055/s-2000-7671
Review
ORIGINALARBEIT
© Georg Thieme Verlag Stuttgart · New York

Recognition and management of acute neuroleptic-induced extrapyramidal motor and mental syndromes

M. Dose
  • BKH Taufkirchen, Germany
Further Information

Publication History

Publication Date:
31 December 2000 (online)

Also available at
 

After nearly 50 years of therapeutic application of neuroleptics, diagnosis and classification of neuroleptic-induced extrapyramidal syndromes still concentrate on their "neurological" (motor) aspects. Psychiatric (mental) aspects are in general - if at all - regarded as “secondary” to motor symptoms. Psychiatric side effects of neuroleptics (including psychotic exacerbations during neuroleptic treatment) have, however, anecdotally been reported since 1954 but never developed into a systematic classification. Accordingly, psychiatric manifestations of extrapyramidal side effects frequently are overlooked, misdiagnosed as psychotic deteriorations and treated by increased dosing of neuroleptics instead anticholinergics, which in addition are falsly suspected of bearing a high addictive potential and the risk of development of tardive dyskinesia. It is suggested that neuroleptic-induced basal ganglia dysfunction results in motor as well as mental extrapyramidal side effects, whose recognition and management is essential to achieve better tolerability of and thereby compliance with neuroleptic treatment.

References

  • 1 Adler L A, Angrist B, Reiter S. et al . Neuroleptic-induced akathisia: a review.  Psychopharmacology. 1989;  97 1-11
    CrossrefPubMedGoogle Scholar
  • 2 Adler L A, Angrist B, Fritz P. et al . Lack of efficacy of d-propranolol in neuroleptic-induced akathisia.  Neuropsychopharmacology. 1991;  4 109-115
    PubMedGoogle Scholar
  • 3 Arnold O H. Schizophrene Exazerbationen: paradoxe Reaktionen auf Intensiv-Neuroleptika. In Kryspin-Exner K, Hinterhuber H, Schubert H, Hrsg. Therapie akuter psychiatrischer Symptome. Schattauer Stuttgart; 1979: 165-168
    Google Scholar
  • 4 Ayd F J. A survey of drug-induced extrapyramidal reactions.  JAMA. 1961;  175 1054-1060
    CrossrefPubMedGoogle Scholar
  • 5 Casey D E. Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia.  Schizophr Res . 1991;  4 109-120
    CrossrefPubMedGoogle Scholar
  • 6 Casey D E. Serotonergic and dopaminergic aspects of neuroleptic-induced extrapyramidal syndromes in nonhuman primates.  Psychopharmacology. 1994;  112 Suppl S55-59
    PubMedGoogle Scholar
  • 7 Casey D E. Extrapyramidal Syndromes. Epidemiology, Pathophysiology and the Diagnostic Dilemma.  CNS Drugs. 1996;  5 Suppl 1 1-12
    PubMedGoogle Scholar
  • 8 Chouinard G, Jones B D. Neuroleptic-induced supersensitivity psychosis: clinical and pharmacological characteristics.  Am J Psychiat. 1980;  137 16-21
    PubMedGoogle Scholar
  • 9 Conrad K, Domanovsky K, Wieser S. Über extrapyramidale Anfallszustände bei Behandlung mit Phenothiazinen.  Neurologie. 1956;  9 505-512
    PubMedGoogle Scholar
  • 10 Coyle J T, Price D L, DeLong M R. Alzheimer's disease: a disorder of cortical cholinergic innervation.  Science. 1983;  219 1184-1190
    PubMedGoogle Scholar
  • 11 Degkwitz R. Die psychische Eigenwirkung der Psychodysleptika.  Hippokrates. 1966;  8 285-290
    PubMedGoogle Scholar
  • 12 Delay J, Deniker P. Le traitement des psychoses par une methode neurolytique derivée de l'hibernotherapy. (Le 4560 R.P. utilisé seul en cure prolongée et continue). Compt rend du Congr des Médecines Alienistes et Neurologistes Luxembourg; 1952
    Google Scholar
  • 13 Delay J, Deniker P. Chlorpromazine and neuroleptic treatments in psychiatry.  J Clin Exp Psychopathol Q Rev Psych Neurol. 1956;  17 19-24
    PubMedGoogle Scholar
  • 14 Dose M. Gibt es ein Abhängigkeitspotential der Anticholinergika?.  TW Neurologie Psychiatrie. 1993;  7 11-13
    PubMedGoogle Scholar
  • 15 Dose M. Anticholinergika in der Psychiatrie. In Barocka A, Hrsg. Psychopharmakotherapie in Klinik und Praxis. Schattauer Stuttgart; 1998: P. 86-93
    Google Scholar
  • 16 Fleischhacker W W, Barnas C, Guenther V. et al . Mood-altering efects of biperiden in healthy volunteers.  J Aff Dis. 1987;  12 153-157
    PubMedGoogle Scholar
  • 17 Fleischhacker W W, Roth S D, Kane J M. The pharmacologic treatment of neuroleptic-induced akathisia.  J Clin Psychopharmacol. 1990;  10 12-21
    PubMedGoogle Scholar
  • 18 Freyhan F A. Psychomotility and parkinsonism in treatment with neuroleptic drugs.  Arch Neurol Psychiat. 1957;  78 465-472
    PubMedGoogle Scholar
  • 19 Gerlach J, Korsgaard S, Clemmesen P. et al . The St. Hans rating scale for extrapyramidal syndromes: reliability and validity.  Acta Psychiatr Scand. 1993;  87 244-252
    PubMedGoogle Scholar
  • 20 Gerlach J, Larsen E B. Subjective experience and mental side-effects of antipsychotic treatment.  Acta Psychiatr Scand. 1999;  99 (Suppl.395) 113-117
    PubMedGoogle Scholar
  • 21 Haag H, Rüther E, Hippius H. Tardive Dyskinesia. WHO Expert Series on Biological Psychiatry. Hogrefe & Huber Vol. I Seattle; 1992
    Google Scholar
  • 22 Haase H -J. Psychiatrische Erfahrungen mit Megaphen (Largactil) und dem Rauwolfiaalkaloid Serpasil unter dem Gesichtspunkt des psychomotorischen Parkinsonsyndroms.  Nervenarzt. 1956;  26 507-510
    PubMedGoogle Scholar
  • 23 Hinterhuber H, Hackenberg B. Neuroleptische Turbulenzphasen. In Hinterhuber H, Schubert H, Kulhanek F, Hrsg. Schattauer Stuttgart; 1986: p. 49-56
  • 24 Hinterhuber H, Haring C. Unerwünschte Wirkungen, Kontraindikationen, Überdosierung, Intoxikation. In Riederer P, Laux G, Pöldinger W, Hrsg. Neuro-Psychopharmaka. Springer Bd 4 Wien; 1992: p. 102-121
    Google Scholar
  • 25 Janzarik W. Zur Psychopathologie der Megaphenwirkung.  Nervenarzt. 1954;  25 330-335
    Google Scholar
  • 26 Johnson A L, Hollister L E, Berger P A. The anticholinergic intoxication syndrome: diagnosis and treatment.  J Clin Psychiatry. 1981;  42 313-317
    PubMedGoogle Scholar
  • 27 Keepers G A, Clappison V J, Casey D E. Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes.  Arch Gen Psychiatry. 1983;  40 1113-1117
    CrossrefPubMedGoogle Scholar
  • 28 Koller W C. Disturbance of recent memory function in parkinsonian patients on anticholinergic therapy.  Cortex. 1984;  20 307-311
    PubMedGoogle Scholar
  • 29 Kulenkampff C, Tarnow G. Ein eigentümliches Syndrom im oralen Bereich bei Megaphenapplikation.  Nervenarzt. 1956;  27 178-180
    PubMedGoogle Scholar
  • 30 Larson E W, Pfenning M A, Richelson E. Selectivity of antimuscarinic compounds for muscarinic receptors of human brain and heart.  Psychopharmacology. 1991;  103 162-165
    PubMedGoogle Scholar
  • 31 McEvoy J P, McCue M, Freter S. Replacement of chronically administered anticholinergic drugs by amantadine in out-patient management of chronic schizophrenia.  Curr Ther. 1987;  9 429-433
    PubMedGoogle Scholar
  • 32 McEvoy J P, McCue M, Spring B. et al . Effects of amantadine and trihexyphenidyl on memory in elderly normal volunteers.  Am J Psychiatry. 1987;  144 573-577
    PubMedGoogle Scholar
  • 33 McEvoy J P, Freter S. The dose-response relationship for memory impairment by anticholinergic drugs.  Compr Psychiatry. 1989;  30 135-138
    CrossrefPubMedGoogle Scholar
  • 34 Meltzer H Y, Matsabura S, Lee J C. Classification of typical and atypical antipsychotic drugs on the basis of D- 1, D- 2 and serotonin pKi values.  J Pharmacol Ext Ther. 1989;  251 238-246
    PubMedGoogle Scholar
  • 35 Naber D, Walther A, Kircher T. et al .Subjective effects of neuroleptics predict compliance. In Gaebel W, Awad R, eds. Prediction of Neuroleptic Treatment Outcome in Schizophrenia. Concepts and Methods. Springer Heidelberg; 1994: p. 85-98
    Google Scholar
  • 36 Remington G, Bezchlibnyk-Butler K. Management of acute antipsychotic-induced extrapyramidal syndromes.  CNS Drugs. 1996;  5 Suppl 1 21-35
    PubMedGoogle Scholar
  • 37 Rogers D. Motor disorder in psychiatry. Towards a neurological psychiatry. Chichester: Wiley & Sons Ltd; 1992: p 65-75
    Google Scholar
  • 38 Schooler N R, Kane J M. Research diagnoses for tardive dyskinesia.  Arch Gen Psychiatry. 1982;  39 486-487
    PubMedGoogle Scholar
  • 39 Schönecker M. Beitrag zu der Mitteilung von Kulenkampff und Tarnow.  Nervenarzt. 1957;  28 155
    PubMedGoogle Scholar
  • 40 Singh M M, Kay S R. Therapeutic antagonism between anticholinergic antiparkinsonian agents and neuroleptics in schizophrenia.  Neuropsychobiol. 1979;  5 74-86
    PubMedGoogle Scholar
  • 41 Steck H. Le syndrome extrapyramidal et diencephalique au cours des traitements au largactil et ou serpasil.  Ann Medico-Psychologiques. 1954;  112 737-743
    PubMedGoogle Scholar
  • 42 Taylor A E, Lang A E, Saint-Cyr A. et al . Cognitive processes in idiopathic dystonia treated with high-dose anticholinergic therapy: implications for treatment strategies.  Clin Neuropharmacol. 1991;  14 62-77
    PubMedGoogle Scholar
  • 43 Uhrbrand L, Faurbye A. Reversible and irreversible dyskinesia after treatment with perphenazine, chlorpromazine, reserpine and electroconvulsive therapy.  Psychopharmacol. 1960;  1 408-418
    CrossrefPubMedGoogle Scholar
  • 44 Van Putten T, Multipassi L R, Malkin M D. Phenothiazine induced decompensation.  Arch Gen Psychiatry. 1974;  30 102-105
    PubMedGoogle Scholar
  • 45 Van Putten T, May P R, Marder S R. Akathisia with haloperidol and thiothixene.  Arch Gen Psychiatry. 1984;  41 1036-1039
    PubMedGoogle Scholar
  • 46 Van Putten T, MarderSR. Behavioral toxicity of antipsychotic drugs.  J Clin Psychiatry. 1987;  48 (Suppl 9) 13-19
    PubMedGoogle Scholar
  • 47 von Dithfurt H. Schauanfälle bei der Zwangskrankheit infolge Megapheneinwirkung.  Nervenarzt. 1957;  4 177-179
    PubMedGoogle Scholar
  • 48 Weiden P J, Mann J J, Haas G. et al . Clinical non-recognition of neuroleptic-induced movement disorders: a cautionary study.  Am J Psychiat. 1987;  114 1148-1153
    PubMedGoogle Scholar
  • 49 World Health Organization. .Prophylactic use of anticholinergics in patients on long-term neuroleptic treatment: a consensus statement. Br J Psychiatry 1990 156: 412
    Google Scholar

Prof. Dr. M. Dose

Psychiatrisches Bezirkskrankenhaus

Bräuhausstraße 5

84416 Taufkirchen

      >